Practitioners Mostly Agree Amgen Won’t Be a Sea Change, But Some Predict Grim Consequences
March 28, 2023
By: Eileen McDermott
IPWatchdog
Axinn counsel Thomas Hedemann and associate Patrick Doyle were quoted in the IPWatchdog article, "Practitioners Mostly Agree Amgen Won’t Be a Sea Change, But Some Predict Grim Consequences."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
Centerforce IP Strategy Summit: Palo Alto
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Pro Bono Partnership 28th Anniversary Gala
Sponsorship
Antitrust
Ronald McDonald House New York Together in Gold Annual Gala
Sponsorship
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust